Partially absorbed antifungal drug (e.g., clotrimazole, miconazole) vs Drug not absorbed from GI tract (e.g., nystatin, amphotericin B)
Outcome not reported · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
Partially absorbed antifungal drug (e.g., clotrimazole, miconazole) vs Absorbed antifungal drug (e.g., fluconazole, ketoconazole, itraconazole)
Outcome not reported · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
Systemic fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs partially absorbed from GI tract (miconazole,… showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs partially absorbed from GI tract (miconazole,… led to lower oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Systemic fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Relief of dysphagia · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Cost of oral care · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Good compliance · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in good compliance compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Length of hospital stay · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Death associated with fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in death associated with fungal infection compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Patient quality of life · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Amount of analgesia · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Relief of pain · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… led to lower oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Adverse effects (side effects; treatment withdrawals) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Johnson 1993 (5 mg tds): sweating 37%, headache 15%, urinary frequency 14%, vasodilatation 12%, dizziness 10%, dyspepsia 10%, nausea 8%, asthenia 8%, diarrhoea 5%; 6% withdrew at 5 mg tds and 29% at 10 mg tds. LeVeque…
2 studies · 278 participants
GRADE not reported
Adverse effects (side effects; treatment withdrawals) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Davies 1994: main side effects with pilocarpine were nausea 20%, sweating 15%, lacrimation 10%. One participant definitely withdrew because of side effects; another may have.
1 study · 20 participants
GRADE not reported
Patient or parental satisfaction (tolerance and acceptability of drug) · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
1 finding from 1 review
Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy
1 finding from 1 review
Xerostomia (dry mouth relief) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Johnson 1993: positive response (>25 mm change in VAS score) in 25% of participants on placebo, 51% on pilocarpine 5 mg tds, 47% on pilocarpine 10 mg tds. LeVeque 1993: positive response in 7% on placebo vs 42% on…
2 studies · 278 participants
GRADE not reported
Other oral symptoms (oral discomfort, dysphonia) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Both studies assessed oral discomfort and dysphonia (Johnson 1993; LeVeque 1993); pilocarpine reported to improve associated symptoms of salivary gland dysfunction (oral discomfort, dysphonia). No pooled data.
2 studies · 278 participants
GRADE not reported